Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,749 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT07279935 | Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.(REVIVE) | recruiting | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06908070 | Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab(CROWD) | recruiting | Phase 4 | 38 | Idris BahceOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07704658 | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 4 | 12 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07754812 | Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC | recruiting | Phase 4 | 78 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | recruiting | Phase 4 | 160 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06646471 | PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies(PROMETHEE) | recruiting | Phase 4 | 500 | GFPC InvestigationOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06330038 | Anesthesia and Non-small Cell Lung Cancer Recurrence(GASTIVA) | recruiting | Phase 4 | 5,384 | Samsung Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07320105 | Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) | recruiting | Phase 4 | 60 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07092202 | Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases | recruiting | Phase 4 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT05525338 | Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels(ADAPT ALEC) | recruiting | Phase 4 | 196 | University Medical Center GroningenOTHER | 2 | May 13, 2024 | clinicaltrials |
| NCT05172739 | Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC | recruiting | Phase 4 | 70 | University of CreteOTHER | 1 | Dec 29, 2021 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials